The purpose of the study is to determine which of the two therapies works better at controlling the disease. Participants will be randomly assigned to receive one of the two treatments, followed by regular check‑ups that may include scans such as positron emission tomography-computed tomography to look for any remaining cancer and assessments of overall health and quality of life. The study continues for several months after treatment to monitor how well the disease is controlled and to record any side effects.

The aim of the trial is to find out how well REC-4881 works and how safe it is for people with this condition. Participants will take the study medication or placebo for several months, with regular visits to have blood tests that look at the drug’s pharmacokinetics—how the body absorbs and clears the medicine—and to check for any side effects. Doctors will also perform examinations of the colon to see how the number and size of polyps, known as polyp burden, change over time.

The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

Participants in the study will receive either Selpercatinib or a combination of the other treatments. The study will monitor the progress of the disease and how the treatments affect it. The treatments will be given through different methods, such as infusion, which is a way of delivering medicine directly into the bloodstream, or oral use, which involves taking medicine by mouth. The study will take place over a period of time, and participants will be closely observed to understand the effects of the treatments.

The study is designed to provide valuable information about the potential benefits of Selpercatinib for patients with RET Fusion-Positive Non-Small Cell Lung Cancer. By comparing it with existing treatments, researchers hope to find the most effective way to manage this type of cancer. The results of this study could lead to improved treatment options for patients in the future.

The purpose of the study is to determine whether the medication can prevent or lessen further disability in people with these disease forms. Participants will take the tablet each day for about 12 months and will visit the clinic at the start, midway, and at the end to check safety and to measure walking ability using a simple 25‑foot walk test called the T25FW. No other experimental treatment will be given.

During the year, participants will keep a short diary of any new symptoms or side effects and will have routine blood checks to monitor health. The final visit will include the same walking test and a review of overall condition. The study is open‑label, meaning the medication being taken is known to both the doctors and the participants.

Participants will be divided by age. Those aged 6 to under 18 will be part of a double‑blind phase where neither the participants nor the doctors know who receives the drug or the placebo, followed by an open‑label phase where everyone receives the active medication. Children younger than 6 will start directly with the active drug in an open‑label part. Over the course of the study, researchers will watch for side effects and will measure simple health indicators such as oxygen saturation (SpO2), lung capacity measured as FVC, and the distance walked in six minutes (6‑min walk distance), as well as growth and quality‑of‑life questionnaires.

During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

Participants in the study will receive either the MK-6194 treatment or a placebo. The study will last for about a year, during which participants will have regular check-ups to monitor their progress. The main focus will be on changes in the skin condition, particularly on the face, over a 24-week period. The study will also keep track of any side effects experienced by participants.

By the end of the study, researchers hope to gather enough information to understand how well MK-6194 works in improving the skin condition and how safe it is for patients. This information could help in developing new treatments for people with non-segmental vitiligo in the future.

The purpose of the trial is to see whether adding the study drug to standard treatment leads to greater overall improvement in symptoms after six weeks. Volunteers are assigned to one of the two groups by chance in a double‑blind manner, meaning neither the participants nor the study staff know who receives the active substance. Over the six‑week period, participants will attend regular visits where simple questionnaires and brief health checks are completed to track changes in mood, anxiety, daily functioning, and overall quality of life. After the treatment phase, participants will have a final follow‑up visit to assess any lasting effects.

Participants in the study will receive either axicabtagene ciloleucel or standard treatments, which may include medications such as prednisone, cyclophosphamide, dexamethasone, vincristine, tocilizumab, doxorubicin, diphenhydramine, rituximab, etoposide, mesna, methylprednisolone, fludarabine, and other analgesics and antipyretics. Some participants may receive a placebo. The study will monitor how well the treatments work by looking at how long participants live without the cancer getting worse and other health outcomes.

The trial will take place over a period of time, during which participants will receive their assigned treatment and have regular check-ups to monitor their health and the progress of the treatment. The goal is to determine which treatment is more effective in improving the lives of people with high-risk large B-cell lymphoma. Participants will be closely monitored for any side effects or changes in their condition throughout the study.

The purpose is to find out whether adding this hormone support increases the chance of a baby being born alive compared with taking no active medication. Participants are randomly assigned to receive either the hormone capsule or the placebo for up to six months while trying to become pregnant naturally. Pregnancy outcomes, any side effects, and quality of life are recorded, and participants are followed for up to 18 months after the start of the study.

The purpose of the trial is to determine whether NXT007 works at least as well as Emicizumab in preventing bleeds. Participants receive regular injections for several months and attend scheduled visits where doctors check their health, collect blood samples, and ask about daily activities and quality of life. The main way the study measures success is by counting the average number of bleeding episodes that need treatment each year, called the annualized number of treated bleeds.

Throughout the study, safety is closely watched. Researchers look for any side effects such as reactions at the injection site, allergic responses, or signs of clotting problems. Participants also complete simple questionnaires about how their condition affects everyday life, helping to assess both the medical and personal impact of the treatments.

The trial will compare the effects of Clazakizumab with a placebo, which is a substance that looks like the medication but does not contain the active ingredient. The study will also use a saline solution, which is a simple saltwater solution, as part of the trial process. The purpose of the study is to determine the best dose of Clazakizumab that can effectively reduce inflammation and to assess its safety in patients with ESKD. Participants will receive the medication or placebo through an intravenous injection, which means it is given directly into a vein.

Throughout the study, researchers will monitor the participants’ health and track any changes in their condition. The study will also look at the impact of Clazakizumab on cardiovascular health, which refers to the health of the heart and blood vessels. This is important because patients with ESKD are at a higher risk of developing heart-related issues. The trial is designed to provide valuable information on how Clazakizumab can help manage inflammation and improve overall health outcomes for patients with ESKD undergoing dialysis.

Participants are randomly assigned to receive either the lower or the standard dose of the albumin infusion at the time of the fluid‑removal procedure and are then followed for up to one year. During this period, they will have regular clinic visits where blood tests and simple questionnaires are used to check for any new health issues, such as infections of the abdominal fluid (spontaneous bacterial peritonitis), kidney problems caused by liver disease (hepatorenal syndrome – acute kidney injury), bleeding from enlarged veins in the esophagus (variceal bleeding), or changes in brain function due to liver failure (hepatic encephalopathy). The study also records overall well‑being and any hospital visits, but no technical details of the measurements are provided.

The study aims to find out whether it is possible to run a larger trial that looks at the added benefit of this extra oxygen treatment. Participants are randomly assigned to either receive the supplemental oxygen sessions or to receive the usual care without the extra oxygen. The trial follows each person for several weeks after surgery, recording how many oxygen sessions are completed and collecting information on recovery and how they feel.

During the study, volunteers will attend regular clinic visits over about 12 weeks. At each visit, doctors will check how the disease is doing using a scoring system called the Modified Mayo Score, which looks at symptoms, a visual exam of the colon (called an endoscopic exam), and lab results. A “clinical remission” means the person’s symptoms have become minimal or disappeared, while a “clinical response” means the symptoms have improved but may not be completely gone. An “endoscopic improvement” indicates that the lining of the colon looks better when viewed with a camera, and “histologic” improvement means that tissue samples show less inflammation under a microscope. Safety will be monitored by recording any side effects and noting if anyone stops the treatment because of them.

The purpose of the study is to watch for any long‑term safety concerns, specifically the chance of developing malignancy caused by insertional oncogenesis, a process where the therapy’s genetic material might unintentionally trigger cancer. After receiving the infusion, participants will have regular sample collections over many years so doctors can check for signs of cancer or unusually high levels of altered cells. This monitoring helps ensure that any potential risks are identified early while the treatment’s benefits continue to be evaluated.

The purpose of the study is to evaluate how effective and safe fidrisertib is for both children and adults with FOP. Participants in the study will take the medication in the form of a hard capsule by mouth. The study will last for a period of up to 60 days, during which participants will be monitored for any changes in their condition and any side effects they might experience. The study will use imaging techniques like computed tomography (CT) to measure changes in bone formation.

Throughout the study, participants will have regular check-ups to assess their health and the progress of their condition. The study aims to provide valuable information on whether fidrisertib can effectively slow down or stop the progression of FOP, offering hope for better management of this challenging condition. Participants will be closely monitored to ensure their safety and well-being during the trial.

The purpose of the study is to determine whether this dose of the drug reduces the likelihood of developing pancreatitis after the procedure. Participants receive the infusion shortly before the ERCP, remain in the hospital for observation, and are checked for abdominal pain, blood test results, and any imaging signs of pancreatitis for up to 48 hours, with additional follow‑up for about a month to monitor any complications or side effects.

After the initial monitoring period, participants may have brief clinic visits or phone calls to assess recovery, quality of life, and any additional medical care needed. A small number of participants will also have blood drawn to measure drug levels, helping researchers understand how the medicine behaves in the body.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

Participants receive three cycles of the infusion, each given several weeks apart, and then are monitored for signs that the disease returns or worsens. Follow‑up includes regular scans and doctor visits to check for any new growths, side effects, or overall health changes. The study records the time until any cancer recurrence, any death related to the disease, and any serious side effects, using standard criteria such as RECIST 1.1 to measure tumor changes.

After the surgery, each person receives the assigned injection—either under the skin (subcutaneous) or into a muscle (intramuscular)—on a schedule set by the study team. Follow‑up visits are planned regularly to check health, monitor any side effects, and assess overall well‑being.

During the study, doctors will watch for any adverse events (unwanted health problems) and ask participants to complete questionnaires about their quality of life and daily functioning. This information helps determine if the treatment is safe and if it improves outcomes compared with the control injection.

Participants receive the drug in a stepwise manner, starting with low doses that are gradually increased to find a level that can be tolerated without serious side effects. Once a safe dose is identified, additional participants receive that dose to see whether the cancer shows signs of shrinking or slowing. Throughout the study, regular visits include physical examinations, blood tests that measure substances such as PSA (a protein that can indicate prostate cancer activity), and imaging scans that create pictures of the inside of the body. Any side effects, changes in laboratory results, or new symptoms are recorded, and the drug may be stopped if safety concerns arise.

The main aim of the study is to see whether this new regimen works better and is safe compared with the usual care for these cancers.

Participants will receive the study medicines in repeated treatment cycles, each lasting a few weeks, with regular check‑ups to monitor tumor size and overall health. Tumor changes are measured using standard imaging and a set of rules called RECIST 1.1. The study looks at how long patients live without the cancer getting worse, known as PFS, and how long patients live overall, referred to as OS. Blood tests and heart checks are done throughout to watch for side effects.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year, with regular clinic visits for injections and health checks. Blood samples will be taken to monitor liver enzymes (ALT and AST), a blood test called the ELF score that estimates liver scarring, and other measures such as cholesterol, blood sugar control (HbA1c), and body weight. Imaging tests, including a special ultrasound that measures liver stiffness (VCTE‑LSM), an MRI‑based scan (MRE), and an MRI that quantifies liver fat (MRI‑PDFF), will be performed at the start and at the end of the study to see how the liver is responding. Any side effects or abnormal lab results will be recorded throughout the study period.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

Participants are randomly assigned to either continue both the pill and the biologic or to stop the pill after a short period. If disease activity rises (a flare), the stopped medication can be started again. All participants keep receiving their regular biologic injections. The study follows each person for up to two years, with clinic visits scheduled at about 3, 6, 12, 18 and 24 months.

At each visit, doctors will check how active the disease is using a score called DAS28-CRP, ask about pain, fatigue and daily function, and record any side effects. Patients will also fill out questionnaires about quality of life and work ability. Blood samples may be taken to measure drug levels. The study aims to compare overall disease control, safety and cost between the two approaches.

The purpose of the trial is to identify a safe and effective dose of the new medication, to see how well it works against these cancers, and to understand how it interacts with other treatments. Early parts of the study increase the dose to find the highest amount patients can tolerate, followed by later parts that treat specific cancer types either alone or combined with the listed drugs. A small group of participants will also receive medicines that are processed by the enzymes CYP3A4 and CYP2C8 to check for possible drug‑interaction effects.

Participants will take the study tablet each day and receive the other medicines by intravenous infusion, meaning the drugs are given through a vein. Regular clinic visits will include physical checks, blood tests, and imaging scans that are evaluated using RECIST criteria, a system that measures how tumor size changes over time. The trial will continue for several months, with close monitoring for side effects, dose adjustments if needed, and assessments of tumor response.

The investigational treatment is an injectable form of efimosfermin alfa, given under the skin (subcutaneous injection). Participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the study staff know which one is given (double‑blind). The study lasts about one year, with regular clinic visits for injections and safety checks.

The main goal is to see whether the drug can improve liver health by reducing inflammation and decreasing scarring (fibrosis) compared with the placebo. Researchers will look at changes in the liver tissue, blood tests, and overall health over the treatment period.

The main goal of the trial is to find the dose of GIA632 that works best for increasing skin color in people with this type of vitiligo. Participants will receive a series of injections over several months, with regular check‑ins to monitor any changes in the appearance of the skin and to watch for possible side effects. The study also uses a simple scoring system called the facial Vitiligo Area Scoring Index to measure how much the facial skin has repigmented, helping researchers understand whether the treatment is effective and safe.

The purpose of the study is to learn about the safety and effects of VERT-002 in treating these types of cancers. The study is divided into two parts. In the first part, researchers will determine the safest dose of VERT-002 and how well patients tolerate it. In the second part, they will further explore the drug’s effects and continue to monitor its safety. The study will help identify the best dose to use in future research.

Participants in the study will receive VERT-002 and will be closely monitored by healthcare professionals. The study will look at how the drug affects the cancer and any side effects that may occur. This research is important for developing new treatments for patients with advanced cancers that have limited options. The study is expected to continue for several years to gather comprehensive data on the drug’s effectiveness and safety.

The purpose of the study is to evaluate the safety and feasibility of gradually extending the dosing interval of these biologic therapies over roughly one year. Participants will receive one of the listed medicines at the regular interval used in routine care, and the interval may be lengthened step by step according to a predefined plan. Throughout the study, individuals will attend regular clinic visits where health status, breathing tests, blood samples, and questionnaire responses are collected.

Safety is monitored by checking for any worsening of symptoms, called an exacerbation, which means a sudden increase in asthma problems lasting more than two days. Blood tests look at the number of eosinophils, a type of white blood cell involved in inflammation, and at the level of exhaled nitric oxide (FeNO), a breath test that reflects airway inflammation. Lung function is measured with the amount of air expelled in the first second (FEV1) and the total amount expelled (FVC). Participants also complete the Asthma Control Questionnaire (ACQ) to rate how well their asthma is controlled, and a lab test called polymerase chain reaction (PCR) may be used to detect viruses during any worsening episodes.

Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

The purpose of the study is to understand how safe and tolerable the new treatment is for patients, as well as to see how well it works in reducing the size of the cancer. Participants in the study will receive the investigational treatment, and their response to the treatment will be monitored over time. The study will also look at how long any positive effects of the treatment last.

Throughout the study, researchers will keep track of any side effects experienced by participants and whether these side effects lead to stopping the treatment. The study aims to gather important information that could help in developing new treatment options for people with this type of cancer. The trial is expected to continue until early 2028.

The purpose of the study is to evaluate how well the VLA15 vaccine works in preventing Lyme disease, as well as to assess its safety and how well it is tolerated by participants. The study will also look at the immune response generated by the vaccine, which is the body’s way of defending itself against infections. Participants in the study will receive a series of injections over a period of time and will be monitored for any reactions or side effects. The study will include people aged 5 years and older who live in areas where Lyme disease is common.

Throughout the study, participants will have regular check-ups to monitor their health and any potential side effects from the vaccine. The study aims to ensure that the vaccine is safe and effective for people of different ages, including children and adults. By participating in this study, researchers hope to gather important information that could lead to a new way to prevent Lyme disease in the future.

The purpose of this study is to compare the effectiveness, safety, and tolerability of the two treatment options over a period of time. Participants will be randomly assigned to one of the two groups and will not know which treatment they are receiving, as the study is double-blind. This means that neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The study will last for a total of 96 weeks, with regular check-ups and assessments to monitor the participants’ health and the virus’s response to the treatment.

Throughout the study, the main focus will be on how well the treatments reduce the amount of HIV-1 RNA in the blood, which is a measure of the virus’s activity. Safety will also be closely monitored by reviewing any side effects or adverse events that participants may experience. The study aims to provide valuable information on the best treatment options for people newly diagnosed with HIV-1, helping to improve their health outcomes and quality of life.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer’s disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer’s disease.